A s with drugs, in the United States, the U.S.
Food and Drug Administration (FDA)
approval is required for the interstate transport and marketing of devices used in the treatment of human disease (1) . Class I devices (e.g., bandages, hand-held surgical instruments) and Class II devices (e.g., infusion pumps, surgical drapes) present the lowest risk to patients and usually do not require clinical trials for marketing approval. Class III devices carry a significant risk of illness or injury, and usually require clinical trials. The approval process for Class III devices that have no "predicate" (i.e., a predecessor-approved device that is similar in function) and have passed preclinical bench and animal testing begins with the filing of an investigational device exemption (IDE). This exemption allows the device to be used in human trials. Further details of medical device classification and approvals, and the IDE application have been discussed in a previous review (1) , and can be found at the FDA's website (2) .
Once a device enters the clinical testing and approval process, the average time to market is 3 to 7 years (1).
Although the time to device approval is significantly shorter than the approval process for new drugs, it is nevertheless lengthy and could prevent patients from accessing device therapy when they most need it for "life-threatening or severely debilitating disease" or "serious diseases or conditions,"
including "sight-threatening and limb-threatening conditions and situations involving irreversible morbidity" (3) . Mechanisms have therefore evolved This review examines the regulatory pathways by which an investigational device or implant that has not begun and/or completed clinical testing can be accessed for patients in urgent need; reviews some of the rules regarding how and when an already approved device may be modified from its strictly approved form for use in an individual patient; and explores future regulatory concerns for personalized devices created in 3D printing processes.
THE CHANGING REGULATORY LANDSCAPE
As the world's oldest consumer protection agency (4), the FDA's primary missions are to assure the efficacy and safety of both drug-and device-based medical therapies. When individual patient need is urgent, and no comparable effective therapy is available, the agency faces a challenge to provide reasonable assurances that devices are both safe and effective, while acknowledging that some patients face markedly elevated risks or disabilities from their own disease or disorder and may be willing to accept significantly higher risks in pursuit of treatment. On the other hand, FDA oversight also serves to prevent deliberate or inadvertent misuse of devices in vulnerable patient populations to further purely commercial interests.
Specific FDA pathways for EA to unapproved medical devices include a compassionate use request (CUR), custom device exemptions (CDEs), and the humanitarian device exemption (HDE). Each of these pathways has unique characteristics that are important to understand in order to determine which is the most appropriate process for use of a specific unapproved device.
Since the 1976 amendments to the Food, Drug, and Cosmetics Act, there have been multiple changes to the FDA rules and regulations regarding the acquisition by physicians of unapproved medical devices for patients facing unique, unusual, or urgent/emergent circumstances.
COMPASSIONATE USE REQUESTS
The FDA uses the term "expanded access" rather than 
D e v i c e s w i t h I D E s .
If the device is subject to an IDE, the sponsor of the IDE (e.g., the investigator, physician, or manufacturer) should submit an IDE supplement that requests approval for EA. Elements that should be included in the supplement are found in Table 3 .
D e v i c e s w i t h o u t I D E s .
If there is no IDE for the device, the physician or manufacturer (because there is no investigator) submits a request including all of the information that would be included in an IDE supplement, except deviations from approved clinical protocols (because there are no "approved protocols" in the absence of an IDE) ( Table 3) . Assistance for submission of a request for expanded use of M o r e t h a n 1 p a t i e n t w i l l b e t r e a t e d . Criteria for a TIDE are summarized in Table 4 (5).
Because an IDE is in place, the application for a TIDE must be made by the IDE sponsor (investigator, physician, or manufacturer). The contents of the application, in the designated order, are provided in Van Norman
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FDA disapproval, or later withdrawal of approval, can occur for a variety of reasons: 1) the application does not meet approval criteria; 2) the FDA determines that any of the grounds for disapproval or withdrawal of approval apply ( Table 6) If a TIDE is granted, the sponsor must submit progress reports, including adverse event reports, on a semiannual basis to all reviewing IRBs and the FDA until the filing of a marketing application. After filing of a marketing application, reports to the FDA are due annually.
HUMANITARIAN DEVICE EXEMPTION
A humanitarian device is one that is expected to diagnose or treat conditions affecting very small groups of patients. The 20th Century Cures Act (8) recently amended the size of the population required to qualify for Humanitarian Use Designation from fewer than 4,000 to "not more than 8,000 in- In that case, the request should indicate that IRB approval will be obtained before use of the device. Proof of approval by the IRB chairperson must be submitted with the follow-up report after the patient is treated.
Abbreviations as in Table 2 . The sponsor of the clinical trial is diligently pursuing marketing approval/clearance of the device *An "immediately life-threatening" disease refers to a disease in which there is a reasonable likelihood that death will occur within months or in which premature death is likely without early treatment.
IDE ¼ investigational device exemption. Sponsor's commitment to meet all applicable responsibilities under the IDE regulations and IRB regulations, and to assure that all participating investigators comply with the informed consent requirements
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Example of the agreement to be signed by all investigators participating in the TIDE and certification that no investigator will be added to the TIDE before it is signed.
If the device is to be sold, the price to be charged and a statement indicating that the price is based on manufacturing and handling costs only.
Applications should be identified on the outside of the envelope as a T IDE application, and reference the original IDE number. An original and 2 copies should be submitted to: Food and Drug Administration, enter for Devices and Radiological Health, Document Mail Center. W066-G609, 10903 New Hampshire Avenue, Silver Springs, Maryland 20993-0002.
TIDE ¼ treatment investigational device exemption; other abbreviations as in Table 2 .
TABLE 6 FDA Grounds for Disapproval or Withdrawal of Approval of a Device
The sponsor has not complied with application requirements of the IDE regulation, any other applicable regulations or statues, or any condition of approval imposed by an IRB or the FDA The application or report contains untrue statements or omits required material information
The sponsor fails to respond to a request for additional information within the time prescribed by the FDA There is reason believe that risks to human subjects are not outweighed by anticipated benefits or the importance of knowledge to be gained
The informed consent is inadequate
The investigation is scientifically unsound
There is reason to believe the device as used is ineffective
It is unreasonable to begin or continue the investigation due to the way the device is used or inadequacy of 1) the report of prior investigations or investigational plan; 2) the methods, facilities and controls used for the manufacturing, processing, packaging, storage, and where appropriate, installation of the device; or 3) the monitoring and review of the investigation Abbreviations as in Table 2 . Table 7 . would be impractical"; 2) the production of the device must be limited to no more than 5 units per year of a particular device type; and 3) a manufacturer is required to submit an annual report to the FDA on the custom devices it has supplied to physicians and patients (18) . A summary of the FDA's decision tree on whether a device is custom can be found in Table 9 (21). The FDA clarified that it now considers CDEs on a per patient rather than per use basis, thus allowing, for example, for bilateral custom orthopedic implants Unusual size: The device has been approved for a wide range of sizes expected to cover a whole patient population, but a patient presents who requires an unusual size outside of that range, and the manufacturer must create an individual size to fit the patient.
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Allergy: If a patient presents with an unusual sensitivity to material that is used in the approved version of the device, the manufacturer may need to create an individual device with special coating or other materials to meet the patient's needs.
Unusual patient disease state: an entirely new type of device is created for an individual patient.
Physician need: a physician needs special instrumentation due to their individual characteristics (e.g., a surgeon missing a finger who needs special instruments or gloves).
Medical facility need: a medical facility may require customized devices for use only in that office, such as special controls on all of its equipment that are not used at other facilities. Is created or modified in order to comply with the order of an individual physician or dentist (or other specially qualified person)
Necessarily deviates from an otherwise applicable performance standard under section 514 or section 515 of the FDCA Is not generally available in the United States in finished form through labelling or advertising by the manufacturer, importer, or distributor for commercial distribution Is designed to treat an unique pathology or physiological condition that no other device is domestically available to treat
Is either a) intended to meet the special needs of such physician or dentist in the course of professional practice of such physician or dentist, or b) is intended for use by an individual patient named in the order of a physician or dentist (or other specially qualified person as designated)
in the same patient to be treated by the manufacturer as only 1 occurrence, provided that both devices are ordered within the same reporting year (21, 22) . Take, for example, the use of an innovative and customized heart valve. The surgeon may be unsure of the exact size needed for the patient until in the middle of the operation-he or she may thus request that the custom device be created in several sizes for intraoperative selection. FDA rules allow the manufacture of more than 1 device in these situations but requires that once a properly sized device is chosen, the unused devices must be returned to the manufacturer and/or destroyed, and the physician must provide a statement certifying that this has been done (21) . A device may become ineligible to be treated as a custom device under a CDE if the manufacturer stockpiles too many of them (13) .
CDE REQUESTS
The regulatory process for custom devices begins Table 3 be instituted as possible (23) . CDEs carry an annual reporting requirement to the FDA. Required elements of the annual report for patient-centric custom devices can be found in Table 10 .
What happens if the FDA determines that a device that was used for patient treatment did not meet CDE requirements? According to the FDA information webinar on CDEs, the FDA notifies the manufacturer in writing the reasons why the device does not qualify for a CDE, with the primary focus of "helping manufacturers [to] implement the Custom Device Exemption correctly and efficiently," however, "the FDA will consider taking enforcement actions when the situation calls for it" (20) . Over the years, the FDA has sent warning letters to several companies alleging that their "custom" devices were in fact customized rather than custom and did not in fact qualify for the exemption. One example is the case of Inter-OS Technologies Inc.-a manufacturer of dental implants-in which the FDA alleged that 2 patients had been implanted with the same prototype device.
Although each had been "customized," the device itself was of the same design, which was not created specifically for each patient (24) . Because the device was denied custom designation, a number of other violations were deemed to therefore have occurred.
The company was accused of failing to obtain informed consent for the implants, and of failure to obtain FDA and IRB approval before enrolling and treating patients-which are required with customized, but not custom, devices. Similarly, the company was accused of failure to adhere to the responsibilities of investigators and sponsors, failure to have written monitoring procedures in place, and failure to maintain device accountability records.
Additional accusations were that the company implanted a third patient after further device modification, and only then submitted an IDE to the FDA, which was disapproved. They were then alleged to have implanted a fourth patient after disapproval of Intended for treatment of a "sufficiently rare" † condition Produced in fewer than 5 units per yr ‡ *"Necessarily deviate" is defined by the FDA as a device that is modified to be sufficiently unique that clinical investigations would be impractical and could not be done to prove conformance to applicable performance standards and/or to support a premarket review. †"Sufficiently rare condition" is defined by the FDA as a condition in a patient population in which the incidence and prevalence is so small that conducting clinical trials would be impractical. ‡See text for further details defining 5 units per yr.
FDA ¼ U.S. Food and Drug Administration.
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the IDE (25) . The company was given 15 days to respond with specific corrective steps (25) .
COMPASSIONATE USE REQUESTS
CURs permit timely review of a custom device that is intended for the unique or unusual circumstance of a particular patient, or a customized device that does not meet all criteria for a CDE. In many cases, CURs can be approved in <30 days by the FDA ( Explanation of how the device satisfies the elements of the FDCA, specifically: B Explanation of why the device "necessarily deviates"* from the pre-market requirements, including treating a sufficiently rare condition that clinical studies are impractical B Indication of whether the device is a newly minted device, or one that has been modified from a legally marketed device B Attestation that the device is not generally available in the United States B Description of the device, including type, and patient's unique pathology or physiology that the device was designed for or modified to treat B Statement that no other device is domestically available to treat the patient's unique pathology or physiology. Records should be maintained of the evaluation that was used to determine that no other device is domestically available B Provision of a unique patient identifier for the treated patient B Statement that the device is assembled from components or manufactured and finished on a case-by-case basis to accommodate the needs of individuals. Finally, a serious concern regarding compassionate use of drugs and devices is that desperate patients seeking life-saving treatment could become victims of exorbitant pricing to access treatments they need.
In response, FDA regulations state that pricing of devices for compassionate use must be based on "manufacturing and handling costs only" (39) . E-mail: lbsparrow@yahoo.com.
